Top

Published in:

02-01-2024 | Breast Cancer

Ovarian Suppression: Early Menopause, Late Effects

Authors: Chaya Goldberg, Megan R. Greenberg, Alexandra Noveihed, Laila Agrawal, Coral Omene, Deborah Toppmeyer, Mridula A. George

Published in: Current Oncology Reports | Issue 5/2024

Abstract

Purpose of Review

Pre-menopausal women diagnosed with hormone receptor (HR) breast cancer are candidates for prolonged hypoestrogenism to improve cancer outcomes. However, the disease benefit eclipses the toxicities associated with ovarian function suppression (OFS), which are often under-reported.

Recent Findings

Increased risk of mortality from cardiovascular disease, bone disorders, and metabolic disorders is well reported in women with no history of cancer, after surgical oophorectomy or premature ovarian failure. Vasomotor symptoms, urogenital atrophy, weight gain, sexual dysfunction, cognitive decline, and sleep disturbances contribute to the increased non-compliance associated with OFS, especially in younger women.

Summary

Balancing the toxicities of prolonged OFS with its benefits should be critically analyzed by providers when making recommendations for their patients. Supportive care to manage multi-system toxicities and to counteract the long-term impact on all-cause mortality should be emphasized by every cancer program. Future studies with OFS should incorporate patient outcomes and strategies for symptom management in addition to focusing on improving disease outcomes.

Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 1896;15:153–79.PubMedPubMedCentral

Paterson R, Russel MH. Clinical trials in malignant disease. Part II-breast cancer: value of irradiation of the ovaries. J Fac Radiol. 1959;10:130–3.CrossRefPubMed

Heer E, Harper A, Escandor N, Sung H, Mccormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–37. https://doi.org/10.1016/S2214-109X(20)30215-1.CrossRefPubMed

Vaz-Luis I, Francis PA, Di Meglio A, Stearns V. Challenges in adjuvant therapy for premenopausal women diagnosed with luminal breast cancers. Am Soc Clin Oncol Educ Book. 2021;41:1–15. https://doi.org/10.1200/EDBK_320595.CrossRefPubMed

Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427. https://doi.org/10.1186/s13058-014-0427-5.CrossRefPubMedPubMedCentral

Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24(36):5769–79. https://doi.org/10.1200/JCO.2006.07.2793.CrossRefPubMed

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37. https://doi.org/10.1056/NEJMoa1803164.CrossRefPubMedPubMedCentral

Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46. https://doi.org/10.1056/NEJMoa1412379.CrossRefPubMed

Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013;22(6):1094–100. https://doi.org/10.1016/j.breast.2013.08.009.CrossRefPubMed

10.

Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol. 2013;121(4):709–16. https://doi.org/10.1097/AOG.0b013e3182864350.CrossRefPubMedPubMedCentral

11.

Rocca WA, Grossardt BR, De Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821–8. https://doi.org/10.1016/S1470-2045(06)70869-5.CrossRefPubMed

12.

Gray RG, Bradley R, Braybrooke J, Clarke M, Hills RK, Peto R, et al. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. J Clin Oncol. 2023;41(16_suppl):503–503. https://doi.org/10.1200/JCO.2023.41.16_suppl.503.CrossRef

13.

Kabirian R, Havas J, Franzoi MA, Coutant C, Tredan O, Levy C, et al. Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): results from the prospective CANTO cohort study. Ann Oncol. 2022;33(7):S1257–S1257. https://doi.org/10.1016/j.annonc.2022.07.1645.CrossRef

14.

Bellet M, Gray KP, Francis PA, Lang I, Ciruelos E, Lluch A, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016;34(14):1584–93. https://doi.org/10.1200/JCO.2015.61.2259.CrossRefPubMedPubMedCentral

15.

Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017;35(27):3113-+. https://doi.org/10.1200/Jco.2016.72.0946.CrossRefPubMedPubMedCentral

16.

Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948–58. https://doi.org/10.1200/JCO.2014.55.6993.CrossRefPubMedPubMedCentral

17.

Li JW, Liu GY, Ji YJ, Yan X, Pang D, Jiang ZF, et al. Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial. Cancer Manag Res. 2019;11:299–307. https://doi.org/10.2147/CMAR.S183672.CrossRefPubMed

18.

Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006;42(7):895–904. https://doi.org/10.1016/j.ejca.2005.12.013.CrossRefPubMed

19.

Kauffman RP, Young C, Castracane VD. Perils of prolonged ovarian suppression and hypoestrogenism in the treatment of breast cancer: is the risk of treatment worse than the risk of recurrence? Mol Cell Endocrinol. 2021;525:111181. https://doi.org/10.1016/j.mce.2021.111181.CrossRefPubMed

20.

Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology. 2010;151(8):3479–89. https://doi.org/10.1210/en.2010-0022.CrossRefPubMedPubMedCentral

21.

Fan Y, Tang R, Prior JC, Chen R. Paradigm shift in pathophysiology of vasomotor symptoms: effects of estradiol withdrawal and progesterone therapy. Drug Discov Today Dis Model. 2020;32:59–69. https://doi.org/10.1016/j.ddmod.2020.11.004.CrossRef

22.

Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848–58. https://doi.org/10.1016/S1470-2045(15)00049-2.CrossRefPubMedPubMedCentral

23.

Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, De Azambuja E, Vaz-Luis I, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–13. https://doi.org/10.1016/S1470-2045(20)30666-5.CrossRefPubMed

24.

Glaser RL, York AE, Dimitrakakis C. Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors. J Clin Oncol. 2014;32(26_suppl):109–109. https://doi.org/10.1200/jco.2014.32.26_suppl.109.CrossRef

25.

Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015;152(2):231–7. https://doi.org/10.1007/s10549-015-3465-5.CrossRefPubMed

26.

Shams T, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014;29(1):204–13.

27.

Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a Randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020;4(1):pkz088. https://doi.org/10.1093/jncics/pkz088.CrossRefPubMed

28.

Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, et al. Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial. Obstet Gynecol. 2023;141(4):737–47. https://doi.org/10.1097/AOG.0000000000005114.CrossRefPubMedPubMedCentral

29.

Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023. https://doi.org/10.1210/clinem/dgad058.CrossRefPubMedPubMedCentral

30.

Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239–46. https://doi.org/10.1097/GME.0000000000002138.CrossRefPubMedPubMedCentral

31.

Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309–18. https://doi.org/10.1016/S1470-2045(11)70364-3.CrossRefPubMedPubMedCentral

32.

Jang S, Ko Y, Sasaki Y, Park S, Jo J, Kang NH, et al. Acupuncture as an adjuvant therapy for management of treatment-related symptoms in breast cancer patients: systematic review and meta-analysis (PRISMA-compliant). Medicine (Baltimore). 2020;99(50):e21820. https://doi.org/10.1097/MD.0000000000021820.CrossRefPubMed

33.

Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010;28(4):634–40. https://doi.org/10.1200/JCO.2009.23.5150.CrossRefPubMed

34.

Marshall-Mckenna R, Morrison A, Stirling L, Hutchison C, Rice AM, Hewitt C, et al. A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Support Care Cancer. 2016;24(4):1821–9. https://doi.org/10.1007/s00520-015-2967-3.CrossRefPubMed

35.

Reid RL, Magee B, Trueman J, Hahn PM, Pudwell J. Randomized clinical trial of a handheld cooling device (Menopod(R)) for relief of menopausal vasomotor symptoms. Climacteric. 2015;18(5):743–9. https://doi.org/10.3109/13697137.2015.1042856.CrossRefPubMed

36.

Composto J, Leichman ES, Luedtke K, Mindell JA. Thermal comfort intervention for hot-flash related insomnia symptoms in perimenopausal and postmenopausal-aged women: an exploratory study. Behav Sleep Med. 2021;19(1):38–47. https://doi.org/10.1080/15402002.2019.1699100.CrossRefPubMed

37.

Maioli S, Leander K, Nilsson P, Nalvarte I. Estrogen receptors and the aging brain. Essays Biochem. 2021;65(6):913–25. https://doi.org/10.1042/EBC20200162.CrossRefPubMedPubMedCentral

38.

Schwartz MD, Mong JA. Estradiol modulates recovery of REM sleep in a time-of-day-dependent manner. Am J Physiol Regul Integr Comp Physiol. 2013;305(3):R271–80. https://doi.org/10.1152/ajpregu.00474.2012.CrossRefPubMedPubMedCentral

39.

Brown, A.M.C. and Gervais, N.J. Role of ovarian hormones in the modulation of sleep in females across the adult lifespan. Endocrinology 2020; 161(9) https://doi.org/10.1210/endocr/bqaa128

40.

Taylor TR, Huntley ED, Makambi K, Sween J, Adams-Campbell LL, Frederick W, et al. Understanding sleep disturbances in African-American breast cancer survivors: a pilot study. Psychooncology. 2012;21(8):896–902. https://doi.org/10.1002/pon.2000.CrossRefPubMed

41.

Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26(5):768–77. https://doi.org/10.1200/JCO.2007.14.3248.CrossRefPubMed

42.

Yeo SM, Lim JY, Kim SW, Chae BJ, Yu J, Ryu JM, et al. Impact of adjuvant hormone therapy on sleep, physical activity, and quality of life in premenopausal breast cancer: 12-month observational study. J Breast Cancer. 2023;26(2):93–104. https://doi.org/10.4048/jbc.2023.26.e11.CrossRefPubMedPubMedCentral

43.

Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol. 2016;34(14):1601–10. https://doi.org/10.1200/JCO.2015.64.8675.CrossRefPubMedPubMedCentral

44.

Cho NY, Kim S, Nowakowski S, Shin C, Suh S. Sleep disturbance in women who undergo surgical menopause compared with women who experience natural menopause. Menopause. 2019;26(4):357–64. https://doi.org/10.1097/GME.0000000000001257.CrossRefPubMed

45.

Hickey M, Moss KM, Krejany EO, Wrede CD, Domchek SM, Kirk J, et al. What happens after menopause? (WHAM): a prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2021;162(2):447–53. https://doi.org/10.1016/j.ygyno.2021.05.036.CrossRefPubMed

46.

Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335–50. https://doi.org/10.1007/s11606-007-0251-z.CrossRefPubMedPubMedCentral

47.

Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res. 2016;5:918. https://doi.org/10.12688/f1000research.8729.3.CrossRefPubMed

48.

Wang SH, Chen WS, Tang SE, Lin HC, Peng CK, Chu HT, et al. Benzodiazepines associated with acute respiratory failure in patients with obstructive sleep apnea. Front Pharmacol. 2018;9:1513. https://doi.org/10.3389/fphar.2018.01513.CrossRefPubMed

49.

Ma Y, Hall DL, Ngo LH, Liu Q, Bain PA, Yeh GY. Efficacy of cognitive behavioral therapy for insomnia in breast cancer: a meta-analysis. Sleep Med Rev. 2021;55:101376. https://doi.org/10.1016/j.smrv.2020.101376.CrossRefPubMed

50.

Makari-Judson G, Viskochil R, Katz D, Barham R, Mertens WC. Insulin resistance and weight gain in women treated for early stage breast cancer. Breast Cancer Res Treat. 2022;194(2):423–31. https://doi.org/10.1007/s10549-022-06624-1.CrossRefPubMed

51.

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8.

52.

Raghavendra A, Sinha AK, Valle-Goffin J, Shen Y, Tripathy D, Barcenas CH. Determinants of weight gain during adjuvant endocrine therapy and association of such weight gain with recurrence in long-term breast cancer survivors. Clin Breast Cancer. 2018;18(1):e7–13. https://doi.org/10.1016/j.clbc.2017.11.006.CrossRefPubMed

53.

Teras LR, Patel AV, Wang M, Yaun SS, Anderson K, Brathwaite R, et al. Sustained weight loss and risk of breast cancer in women 50 years and older: a pooled analysis of prospective data. J Natl Cancer Inst. 2020;112(9):929–37. https://doi.org/10.1093/jnci/djz226.CrossRefPubMed

54.

Bandera EV, Qin B, Lin Y, Zeinomar N, Xu B, Chanumolu D, et al. Association of body mass index, central obesity, and body composition with mortality among black breast cancer survivors. JAMA Oncol. 2021;7(8):1–10. https://doi.org/10.1001/jamaoncol.2021.1499.CrossRefPubMedPubMedCentral

55.

Bui KT, Willson ML, Goel S, Beith J, Goodwin A. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochr Database Syst Rev. 2020;3(3):CD013538. https://doi.org/10.1002/14651858.CD013538.CrossRef

56.

Zhang P, Li CZ, Jiao GM, Zhang JJ, Zhao HP, Yan F, et al. Effects of ovarian ablation or suppression in premenopausal breast cancer: a meta-analysis of randomized controlled trials. Eur J Surg Oncol. 2017;43(7):1161–72. https://doi.org/10.1016/j.ejso.2016.11.011.CrossRefPubMed

57.

Juvet LK, Thune I, Elvsaas IKO, Fors EA, Lundgren S, Bertheussen G, et al. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: a meta-analysis. Breast. 2017;33:166–77. https://doi.org/10.1016/j.breast.2017.04.003.CrossRefPubMed

58.

Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114(9):956–64. https://doi.org/10.1038/bjc.2016.71.CrossRefPubMedPubMedCentral

59.

Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET. Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology. 2019;106:9–19. https://doi.org/10.1016/j.psyneuen.2019.03.013.CrossRefPubMed

60.

Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, De Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–83. https://doi.org/10.1212/01.wnl.0000276984.19542.e6.CrossRefPubMed

61.

Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM. Association of premenopausal bilateral oophorectomy with cognitive performance and risk of mild cognitive impairment. JAMA Netw Open. 2021;4(11):e2131448. https://doi.org/10.1001/jamanetworkopen.2021.31448.CrossRefPubMedPubMedCentral

62.

Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther. 2012;135(1):54–70. https://doi.org/10.1016/j.pharmthera.2012.03.007.CrossRefPubMedPubMedCentral

63.

Jordan, J.H., D’agostino, R.B., Jr., Ansley, K., Douglas, E., Melin, S., Sorscher, S. et al. Myocardial function in premenopausal women treated with ovarian function suppression and an aromatase inhibitor. JNCI Cancer Spectr 2021; 5(4) https://doi.org/10.1093/jncics/pkab071

64.

Chou YS, Wang CC, Hsu LF, Chuang PH, Cheng CF, Li NH, et al. Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: a cohort study. Cancer Med. 2023;12(5):5536–44. https://doi.org/10.1002/cam4.5390.CrossRefPubMed

65.

Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021;28:100355. https://doi.org/10.1016/j.jbo.2021.100355.CrossRefPubMedPubMedCentral

66.

Stumpf U, Kostev K, Kyvernitakis J, Bocker W, Hadji P. Incidence of fractures in young women with breast cancer - a retrospective cohort study. J Bone Oncol. 2019;18:100254. https://doi.org/10.1016/j.jbo.2019.100254.CrossRefPubMedPubMedCentral

67.

Go J, Park S, Kim KS, Kang MC, Ihn MH, Yun S, et al. Risk of osteoporosis and fracture in long-term breast cancer survivors. Korean J Clin Oncol. 2020;16(1):39–45. https://doi.org/10.14216/kjco.20007.CrossRefPubMedPubMedCentral

68.

Leslie WD, Morin SN, Lix LM, Niraula S, Mccloskey EV, Johansson H, et al. Fracture risk in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study. Oncologist. 2019;24(11):1432–8. https://doi.org/10.1634/theoncologist.2019-0149.CrossRefPubMedPubMedCentral

69.

Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916–46. https://doi.org/10.1200/JCO.19.01696.CrossRefPubMed

70.

Leslie WD, Morin SN, Lix LM, Niraula S, Mccloskey EV, Johansson H, et al. Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a Registry-Based Cohort study. J Bone Miner Res. 2019;34(8):1428–35. https://doi.org/10.1002/jbmr.3726.CrossRefPubMed

71.

Ishikawa T. Differences between zoledronic acid and denosumab for breast cancer treatment. J Bone Miner Metab. 2023;41(3):301–6. https://doi.org/10.1007/s00774-023-01408-z.CrossRefPubMed

72.

Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–63. https://doi.org/10.1016/j.annonc.2020.07.019.CrossRefPubMed

73.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313–20. https://doi.org/10.1093/annonc/mdu544.CrossRefPubMed

74.

Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):60–72. https://doi.org/10.1016/S1470-2045(19)30687-4.CrossRefPubMed

75.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339–51. https://doi.org/10.1016/S1470-2045(18)30862-3.CrossRefPubMed

76.

Hanson A, G.J., Ormerod C, Katze N, Teteh D, Ericson M. Living beyond breast cancer; Chapman University. The changing informational needs of young women affected by breast cancer: a national needs assessment. In 2022.

77.

Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492–511. https://doi.org/10.1200/JCO.2017.75.8995.CrossRefPubMed

78.

Carter J, Baser RE, Goldfrank DJ, Seidel B, Milli L, Stabile C, et al. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Support Care Cancer. 2021;29(1):311–22. https://doi.org/10.1007/s00520-020-05472-3.CrossRefPubMed

79.

Goldfarb SB, et al. Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy. J Clin Oncol. 2023;41(16_suppl):12015.

80.

The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstetr Gynecol 2016; 127(3): E93-E96.

81.

Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause-the J North Am Menopause Soc. 2018;25(6):596–608. https://doi.org/10.1097/Gme.0000000000001121.CrossRef

82.

Pederson HJ, Faubion SS, Pruthi S, Goldfarb S. RE: systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2023;115(2):220–1. https://doi.org/10.1093/jnci/djac211.CrossRefPubMed

83.

Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361–70. https://doi.org/10.1097/GME.0000000000001463.CrossRefPubMed

84.

Archer DF, Constantine GD, Simon JA, Kushner H, Mayer P, Bernick B, et al. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause-the J North Am Menopause Soc. 2017;24(5):510–6. https://doi.org/10.1097/Gme.0000000000000790.CrossRef

85.

Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(4):1335–43. https://doi.org/10.1007/s00520-017-3960-9.CrossRefPubMed

86.

Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2011;126(2):443–51. https://doi.org/10.1007/s10549-010-1332-y.CrossRefPubMed

87.

Lee YJ, Wu ZY, Kim HJ, Lee JW, Chung I, Kim J, et al. Change in estradiol levels among premenopausal patients with breast cancer treated using leuprolide acetate 11.25 milligrams 3-month depot and tamoxifen. J Breast Cancer. 2020;23(5):553–9. https://doi.org/10.4048/jbc.2020.23.e57.CrossRefPubMedPubMedCentral

Title: Ovarian Suppression: Early Menopause, Late Effects
Authors: Chaya Goldberg
Megan R. Greenberg
Alexandra Noveihed
Laila Agrawal
Coral Omene
Deborah Toppmeyer
Mridula A. George
Publication date: 02-01-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Tamoxifen
Estrogens
Published in: Current Oncology Reports / Issue 5/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01491-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2024

Perioperative Neurocognitive Function in Glioma Surgery

Patient Navigation in Cancer Treatment: A Systematic Review

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer

Immune Checkpoint Inhibitors in Geriatric Oncology

Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update

Current Trends and Challenges of Microbiome Research in Prostate Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer